Protein map of rare childhood cancer could reveal new attack points
NCT ID NCT04868799
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at protein patterns in tumor samples from 44 children with a rare cancer called rhabdoid tumor. Researchers used advanced techniques to see how tumors differ from each other. The goal was to find new targets for future treatments. The study is complete and did not test any new drug.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this research could point toward new drug targets for treating rhabdoid tumors, a rare childhood cancer.
- What could go wrong
- This is a small, completed lab study, not a treatment trial. The findings may not lead to new therapies or may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATRT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Service de neurochirurgie - Hôpital Necker Enfants malades
Paris, 75015, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Targeted radiation zaps childhood brain tumors in early trial
- Experimental drug tazemetostat offered to patients with rare, aggressive tumors
- New hope for kids with Hard-to-Treat cancers: targeted drug shows promise
- New drug targets tough childhood cancers with genetic flaws
- New stem cell transplant shows promise for kids with tough cancers
- Immunotherapy drug nivolumab takes on rare childhood cancer